#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

Less than a week af­ter Ei­sai and Bio­gen won ac­cel­er­at­ed ap­proval from the FDA for their Alzheimer’s drug lecanemab, Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER